The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It all sounds very interesting / exciting .... But I will wait until this appears in a Peer-reviewed journal, my concern is that that none of their research seems to be published
Sam will be happy with that, but what about those that have dumped shares in ROQ over the last week after todays RNS,
Quicker than Sam Allardyce.
It's becoming clearer to me by the day, the more time I spent research ROQ personnel. The commonality of why these people appear in the media is for me eye popping.
https:// forbetterscience .com/2019/07/15/questionable-activities-of-uk-company-celixir-by-patricia-murray/
https://forbetterscience .com/2019/04/04/sir-martin-and-ajan-the-stem-cell-gold-diggers/
https://www. ft .com/content/41a4e01a-d3b6-11de-8caf-00144feabdc0
You have to ask yourself, if you were a big pharma now and did your DD on buying ROQ or investing in ROQ wouldn't you want answers on ROQ's personnel's back stories??
Just watched the IG.com interview with Ajan (https://www.youtube.com/watch?v=cvRtMDvdPLU)
Had to chuckle when he said (12m:45s) 'if we deliver our milestones and the data for the last 15 years is accurate'
Have that statement about data being accurate in mind when you read the publicly available article
https://forbetterscience.com/2019/07/15/questionable-activities-of-uk-company-celixir-by-patricia-murray/
Ajan talks about data over the last 15 years, which covers the period that the Celixir Greek trial in Patricia's Murrays article.
Questions
Will the data obtained in the Greek trials be included in ROQ clinical data?
Will the data for the last 15 years be accurate?
Having watched the IG.com interview with Ajan (https://www.youtube.com/watch?v=cvRtMDvdPLU) where he states (12m:45s) 'if ....... the data for the last 15 years is accurate' I continue to wonder where ROQ are going to get 15 years of data from. Does it include research from Celixir? Where Ajan previously worked.
I found these Editorial Expression of Concern (https://link.springer.com/article/10.1007/s12265-020-10076-7) for a paper that Ajan is a co-author. In which it states "Following an investigation into a number of concerns raised in relation to this article after publication, the journal has found that the study did not receive all necessary approvals from regulatory and ethical bodies......our investigation has found that advance approvals were not obtained from the National Ethics Committee nor the National Organizations for Medicines, as required for clinical trials conducted in Greece. "
The Editorial Expression of Concern also states "After reviewing the raw data, discrepancies can be found between the estimated and calculated LVEF data. As this raises questions about the accuracy of the method to determine whether patients met the inclusion criterion of an LVEF of less than 40%, the readers are advised to interpret the findings related to the baseline LVEF data with caution."
Celixir undertook these trial in Greece. So does the 15 years of data that Ajan refers to include the Greece trial that reportedly didn't have all necessary approvals from regulatory and ethical bodies and that readers are advised to interpret the findings related to the baseline LVEF data with caution?
A second Editorial Expression of Concern (EEoC) regarding a different paper that Ajan is a co-author. (https://www.researchgate.net/publication/348851881_Expression_of_Concern_STAT6_knockdown_using_multiple_siRNA_sequences_inhibits_proliferation_and_induces_apoptosis_of_human_colorectal_and_breast_cancer_cell_lines).
This EEoC states "Questions were raised post-publication as to whether the results and conclusions are adequately supported given that the experiments were conducted only in a single cell line per cancer type, lacked some controls, and sample sizes were low (as few as two replicates for some experiments). Questions were also raised about the validity of the statistical analyses reported in the article" and "A statistical reviewer reviewed the article and underlying dataset and raised concerns about the assumptions made about normality and equal variances. The article did not report evidence to support these assumptions or information about how the authors assayed for normality and equal variances."
Have a read of both Editorial Expression of Concerns
So I ask again, where does ROQ get 15 years of data from? For me it just doesn't add up.
Wonder which way this is going when it relists?
Https://www.bbc.co.uk/news/business-43415967
I like the bit where it states "Innovators who seek to revolutionise and disrupt an industry must tell investors the truth about what their technology can do today - not just what they hope it might do someday."
With ROQ now suspended for over a month due to not producing the accounts on time, interesting to see if the BoD will inform the market regarding the truth about what ROQ's technology can do today - not just what they hope it might do someday.
Got no Seoul.
I remember when USOP was ramped and got suspended and went Dutch.
Went from 30p to £6:20
The good old days.
Proper ramps, every one had a BMX
Suspended 2nd May 2023 and here we are still suspended a month later. In my opinion, something doesn't smell too good.
Been suspended for 3 weeks as of today, still no sign of the accounts?????
I am sorry but I can name you countless biotech companies pre-clinical on LSE that are no where near £55million. Again I am sure you can pull data that suits an agenda maybe different countries and not taking into account cash, revenue, timelines, fundamentals.
ROQ RTOd a company with patents, so on same basis I can do the same for a few £million and I am now worth £55million? Does not make any sense.
I'm no longer going to waste my time talking to you. Your reply quite frankly shows your total ignorance . If you had indeed you had looked at all research reports on Roquefort by market professionals and indeed studied all presentations by Roquefort you will see that you're wrong but I know you won't.....................so goodbye
Wait a minute did you really just say any company pre-clinical trials is valued at £55million?
Looking at biotech valuations and then make a blanket statement without taking into account, cash, finance, revenue, deals, management, fundamentals, milestones, technology and so on has to be one of the most silly things I have heard in a long time.
And still no answer to my questions!!!!.
I am sorry, because I've spent 30 years as an Institutional Equity salesman promoting companies to fund managers across Asia, Europe ans the US. I have experience of failed management, which in HK is particularly prevalent . I'm very aware of the articles re Ajan, and I've researched much before investing in ROQ . I was first put on to Roquefort by a very wealthy and successful Family fund in Singapore but based in Switzerland.
Any Investors reading this should take note. I believe that Roquefort should and will most probably be sold at one pound sterling within this year.
Reason.....any company entering clinical trials is worth 55M sterling( this is not conjecture. It's fact) That alone equates to 40 pence price on the stock. ROQ have two, both taken on by the UK's biggest diagnostic company and one of the world's leaders. By December, at latest, and of course if successful this value will be recognized.
They have three more potentials which are rapidly realizing their value . The same as above applies. In the wings are many institutional investors. I can tell you from experience that no public money can be invested in Roquefort at it's value today. All public funds have investment criteria. ROQ falls short for two reasons;
1. Market cap is too small . It's a micro cap. This precludes most funds.
2. Volume of trades or LIQUIDITY ( all public money can't invest more than it can sell within two to thee days should it need to realize cash for the share holders.
But once a diagnostic or big Farma company makes a bid, that pound is easy.
I do however offer some sanity here. It may not happen of course, but the risk reward ratio in heavily in favor of ROQ now.
At 8 pence the CEO, a VC Company and a Japanese Pharmaceutical Company took a placement at 14 pence 75% market price. I've completed many placements in my career. Every one has been at a discount to market price in order to persuade investors to get in. Ajan didn't want any investor to be diluted, and he put his money in at this price.
Randox. The biggest UK diagnostics company has put it's weight behind ROQ.
I'm very hopeful for it's success, and It's my biggest weighting in my investment portfolio by a long way.
By the way. I'm Stephen Clemenson. Clemensonsteve@gmail.com should ytou want to talk privately re investments, or to check my profile.
I said you could do some research, don't base your investment strategies on listening to other people on bulletin boards. Your comments (If you ever came out with some insight as to the investment merits or risks of Roq I would listen) probably says more about you than me. Good luck, tell me, did you get your investment advice re: ROQ from Twitter?
If you ever came out with some insight as to the investment merits or risks of Roq I would listen, but just slinging spurious insults at an individual shows your complete ignorance .
Maybe you should do some. All your comments are on one guy!!!!!
Clemenson
It's called research. Maybe you should do some on ROQ.
You'll only have to wait a few more months before all your arguments are proven to be null and void. I do still wonder what makes you spend so much time on a company that you're not even invested in.......hahahahha
Nothing better to do I guess
Watermelõn, I can always tell when I getting near the truth.
Ajan has done deals with Randox and Daiichi Sankyo, and worked for Roche.
Sausage is a shareholder in SYN and EDL.
Says it all really.
So has your research led you to invest or not invest. I wonder if not invest then why are you wasting your time
Meet me in London. I’ll give you a bare knuckle be.ating
The struck off dentist aspect, for me, is a red herring. It's irrelevant. If the governing body of your profession think you are so sh 1 t they strike you off, then you need a new career.
My concern is Ajan background in pharma, which I'm getting a feeling people don't want to discuss so focus on the struck of dentist aspect.
To me, your response has a feeling of sweeping it under the carpet.
I'm sure you are encouraging people to fully research companies they may wish to buy into, aren't you?